The present invention relates to synthetic leopeptides of formula Cn-X1-X2-X3-NH2 , wherein: Cn is a fatty acid selected from the group consisting of C12 to C16； X1 is at least one glycine molecule； X2 is at least two natural amino acids that have a positive net charge and/or are not proteinogenic； and X3 can be present or absent, and when it is present it is at least one aliphatic amino acid. The lipopeptides have antimicrobial activity against pathogenic bacteria (Staphylococcus aureus, Enterococcus faecalis, Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumoniae, Acinetobacter baumannii, Serratia marcescens, Staphylococcus saprophyticus, Staphylococcus haemolyticus and Streptococcus salivarius), at minimum inhibitory concentrations (MIC) between 8 and 50 µM. In addition, they do not display toxicity in human red blood cells or in mosquito larvae in concentrations between 3.13 and 50.0 µM at an evaluated concentration of 100 µM.La presente invención se refiere a lipopéptidos sintéticos de fórmula Cn-X1-X2-X3-NH2 en donde: Cn es un ácido graso seleccionado del grupo que consiste de C12 a C16； X1 es al menos una molécula de glicina； X2 es al menos dos aminoácidos naturales con carga neta positiva y/o no proteinogénicos； y, X3 puede estar presente o ausente y cuando está presente es al menos un aminoácido alifático, Los lipopéptidos presentan actividad antibacteriana contra bacterias patógenas (Staphylococcus aureus, Enterococcus faecalis, Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumoniae, Acinetobacter baumannii, Serratia marcescens, Staphylococcus saprophyticus, Staphylococcus haemolyticus y Streptococcus salivarius) a concentraciones mínimas inhibitorias (CMI) entre 8 a 50 µM. Adicionalmente, no presentaron toxicidad en eritrocitos humanos ni en larvas de mosquito en concentraciones entre 3,13 y 50,0 µM a una concentración evaluada de 100 µM.La présente invention concerne des lipopeptides synthétiques de formule Cn-X1-X2-X3-NH2 dans laquel
